Radiopharmaceuticals
We are the leader in Poland in the production of radiopharmaceuticals for PET-CT studies.
Polish manufacturer and distributor of radiopharmaceuticals
We are a manufacturer and distributor of radiopharmaceuticals for Positron Emission Tomography (PET), used in oncological, cardiological and neurological diagnostics.
We are a radiopharmaceutical wholesaler. We remain independent both as a manufacturer and as a supplier. We can provide radiopharmaceuticals to the PET/CT both in Poland and abroad.
The highest quality products
Our products are manufactured in accordance with GMP and national standards. Our employees are some of the most experienced in the sector.
Our guiding principle is quality. We apply it both to our products and for to our customer service.
Read more about how the activities related to sources of ionizing radiation impact human health and the environment.
Production of radiopharmaceuticals
Manufacturing of radiopharmaceuticals takes place at three separate sites
Świętokrzyskie Oncology Centre in Kielce
It is one of the most important centers in Poland focused on the oncological care of patients offering diagnostic, treatment and rehabilitation services.
Military Institute of Medicine in Warsaw
Production plant in Mszczonów
In specially prepared and equipped rooms we conduct radioisotope manufacturing, synthesis and quality control.
Indications for use and information about medicinal products
| Product | Details | Action |
|---|---|---|
| FLT (18F) Synektik | Tracer desinged to determine the localization of malignant tumours due to its ability to detect the product in cells with increased mitotic activity in adults | Download |
| Fludeoxyglucose (18F) Synektik | Tracer for use with positron emission tomography (PET) in oncological, cardiological, neurological, and infectious and inflammatory diseases diagnostic procedures | Download |
| Fluorocholine (18F) Synektik | Tracer for use with positron emission tomography (PET) in detection of bone metastases of prostate cancer and hepatocellular carcinoma | Download |
| GalliaPharm 1,11 GBq - 3,70 GBq generator | Pharmaceutical product for obtaining the positron emitter Gallium (68) for production of labelled tracers (for example peptides) | Download |
| Glunektik | Tracer for use with positron emission tomography (PET) in oncological, cardiological and neurological diagnostic procedures and infectious and inflammatory diseases | Download |
| IASOdopa (is available by means of direct import procedure only) | Tracer for use with positron emission tomography (PET) in oncological and neurological diagnostic procedures | Download |
| IASOglio | Tracer for use with positron emission tomography (PET) when enhanced amino acids consumption of sick organs or tissues is the diagnostic target | Download |
| Ioflupane (123I) ROTOP | Tracer indicated for the detection of a reduction in the number of functional dopaminergic neuronal endings in the striatum | Download |
| NanoSPECT | Tracer is used for diagnostic scintigraphy and evaluation of: bone marrow, inflammatory conditions, state of the lymphatic system , in the differential diagnosis of venous and lymphatic stasis, evaluation of sentinel nodes in cancer | Download |
| Natrii fluoridum (18F) Synektik | Tracer for use with positron emission tomography (PET) in diseases where abnormally altered osteogenic activity is the diagnostic target | Download |
| Yttriga | Radiopharmaceutical precursor to be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide | Download |
| Product | Details | Action |
|---|---|---|
| FLT (18F) Synektik | Tracer desinged to determine the localization of malignant tumours due to its ability to detect the product in cells with increased mitotic activity in adults | Download |
| Fludeoxyglucose (18F) Synektik | Tracer for use with positron emission tomography (PET) in oncological, cardiological, neurological, and infectious and inflammatory diseases diagnostic procedures | Download |
| Fluorocholine (18F) Synektik | Tracer for use with positron emission tomography (PET) in detection of bone metastases of prostate cancer and hepatocellular carcinoma | Download |
| GalliaPharm 1,11 GBq - 3,70 GBq generator | Pharmaceutical product for obtaining the positron emitter Gallium (68) for production of labelled tracers (for example peptides) | Download |
| Glunektik | Tracer for use with positron emission tomography (PET) in oncological, cardiological and neurological diagnostic procedures and infectious and inflammatory diseases | Download |
| IASOglio | Tracer for use with positron emission tomography (PET) when enhanced amino acids consumption of sick organs or tissues is the diagnostic target | Download |
| Ioflupane (123I) ROTOP | Tracer indicated for the detection of a reduction in the number of functional dopaminergic neuronal endings in the striatum | Download |
| NanoSPECT | Tracer is used for diagnostic scintigraphy and evaluation of: bone marrow, inflammatory conditions, state of the lymphatic system , in the differential diagnosis of venous and lymphatic stasis, evaluation of sentinel nodes in cancer | Download |
| Natrii fluoridum (18F) Synektik | Tracer for use with positron emission tomography (PET) in diseases where abnormally altered osteogenic activity is the diagnostic target | Download |
| Yttriga | Radiopharmaceutical precursor to be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide | Download |
Reporting of Adverse Reactions
It is the obligation of the Marketing Authorization Holder to ensure that any aspect which could impact the safety profile of the authorized medicinal products is detected and assessed and that the necessary measures are taken. This monitoring is called pharmacovigilance and requires collecting and managing data on the safety of medicines. In particular, it concerns in particual information regarding Adverse Reactions caused by the medicinal products.
For more information or to report a side effect, please click on the button below.
